{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:56:58Z","timestamp":1773043018592,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05197-y","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T08:02:42Z","timestamp":1661673762000},"page":"1087-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of semaphorin 3A and semaphorin 7A levels in primary Sjogren's syndrome"],"prefix":"10.1007","volume":"43","author":[{"given":"Emre","family":"Urhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse Camci","family":"Urhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halef Okan","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"key":"5197_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","volume":"22","author":"S Negrini","year":"2022","unstructured":"Negrini S, Emmi G, Greco M et al (2022) Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease. Clin Exp Med 22:9\u201325. https:\/\/doi.org\/10.1007\/s10238-021-00728-6","journal-title":"Clin Exp Med"},{"key":"5197_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","volume":"34","author":"MI Christodoulou","year":"2010","unstructured":"Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM (2010) Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren\u2019s syndrome. J Autoimmun 34:400\u2013407. https:\/\/doi.org\/10.1016\/j.jaut.2009.10.004","journal-title":"J Autoimmun"},{"key":"5197_CR3","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zeron","year":"2016","unstructured":"Brito-Zeron P, Baldini C, Bootsma H et al (2016) Sj\u00f6gren syndrome. Nat Rev Dis Prim 2:16047. https:\/\/doi.org\/10.1038\/nrdp.2016.47","journal-title":"Nat Rev Dis Prim"},{"key":"5197_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221100295","author":"SZ Callegher","year":"2022","unstructured":"Callegher SZ, Giovannini I, Zenz S et al (2022) Sj\u00f6gren syndrome: looking forward to the future. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X221100295","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5197_CR5","first-page":"161","volume":"34","author":"F Ferro","year":"2016","unstructured":"Ferro F, Vagelli R, Bruni C et al (2016) One year in review 2016: Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol 34:161\u2013171","journal-title":"Clin Exp Rheumatol"},{"key":"5197_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11882-013-0357-9","volume":"13","author":"G Stojan","year":"2013","unstructured":"Stojan G, Baer AN, Danoff SK (2013) Pulmonary manifestations of Sj\u00f6gren\u2019s syndrome. Curr Allergy Asthma Rep 13:354\u2013360. https:\/\/doi.org\/10.1007\/s11882-013-0357-9","journal-title":"Curr Allergy Asthma Rep"},{"key":"5197_CR7","doi-asserted-by":"publisher","first-page":"645967","DOI":"10.1155\/2012\/645967","volume":"2012","author":"GJ Tobn","year":"2012","unstructured":"Tobn GJ, Pers JO, Devauchelle-Pensec V, Youinou P (2012) Neurological disorders in primary Sj\u00f6gren\u2019s syndrome. Autoimmune Dis 2012:645967. https:\/\/doi.org\/10.1155\/2012\/645967","journal-title":"Autoimmune Dis"},{"key":"5197_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","volume":"88","author":"E Baimpa","year":"2009","unstructured":"Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sj\u00f6gren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88:284\u2013293. https:\/\/doi.org\/10.1097\/MD.0b013e3181b76ab5","journal-title":"Medicine (Baltimore)"},{"key":"5197_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.rdc.2017.09.010","volume":"44","author":"Y Popov","year":"2018","unstructured":"Popov Y, Salomon-Escoto K (2018) Gastrointestinal and hepatic disease in Sjogren syndrome. Rheum Dis Clin North Am 44:143\u2013151. https:\/\/doi.org\/10.1016\/j.rdc.2017.09.010","journal-title":"Rheum Dis Clin North Am"},{"key":"5197_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","volume":"53","author":"C Baldini","year":"2014","unstructured":"Baldini C, Pepe P, Quartuccio L et al (2014) Primary Sjogren\u2019s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 53:839\u2013844. https:\/\/doi.org\/10.1093\/rheumatology\/ket427","journal-title":"Rheumatology (Oxford)"},{"key":"5197_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/gb-2006-7-3-211","volume":"7","author":"U Yazdani","year":"2006","unstructured":"Yazdani U, Terman JR (2006) The semaphorins. Genome Biol 7:211. https:\/\/doi.org\/10.1186\/gb-2006-7-3-211","journal-title":"Genome Biol"},{"key":"5197_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ni1553","volume":"9","author":"K Suzuki","year":"2008","unstructured":"Suzuki K, Kumanogoh A, Kikutani H (2008) Semaphorins and their receptors in immune cell interactions. Nat Immunol 9:17\u201323. https:\/\/doi.org\/10.1038\/ni1553","journal-title":"Nat Immunol"},{"key":"5197_CR13","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/eji.200535601","volume":"36","author":"Y Lepelletier","year":"2006","unstructured":"Lepelletier Y, Moura IC, Hadj-Slimane R et al (2006) Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol 36:1782\u20131793. https:\/\/doi.org\/10.1002\/eji.200535601","journal-title":"Eur J Immunol"},{"key":"5197_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.gene.2017.02.013","volume":"610","author":"M Rezaeepoor","year":"2017","unstructured":"Rezaeepoor M, Shapoori S, Ganjalikhani-hakemi M et al (2017) Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients. Gene 610:59\u201363. https:\/\/doi.org\/10.1016\/j.gene.2017.02.013","journal-title":"Gene"},{"key":"5197_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00296-015-3269-2","volume":"35","author":"D Rimar","year":"2015","unstructured":"Rimar D, Nov Y, Rosner I et al (2015) Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatol Int 35:1625\u20131630. https:\/\/doi.org\/10.1007\/s00296-015-3269-2","journal-title":"Rheumatol Int"},{"key":"5197_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1177\/0961203312456753","volume":"21","author":"Z Vadasz","year":"2012","unstructured":"Vadasz Z, Toubi E (2012) Semaphorin 3A \u2013 a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. Lupus 21:1266\u20131270. https:\/\/doi.org\/10.1177\/0961203312456753","journal-title":"Lupus"},{"key":"5197_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/ar3881","volume":"14","author":"Z Vadasz","year":"2012","unstructured":"Vadasz Z, Haj T, Halasz K et al (2012) Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res Ther 14:146","journal-title":"Arthritis Res Ther"},{"key":"5197_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2474-14-40","volume":"14","author":"S Takagawa","year":"2013","unstructured":"Takagawa S, Nakamura F, Kumagai K et al (2013) Decreased Semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis. BMC Musculoskelet Disord 14:40","journal-title":"BMC Musculoskelet Disord"},{"key":"5197_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jmii.2017.07.001","volume":"52","author":"HT Liao","year":"2019","unstructured":"Liao HT, Lin YF, Chou CT, Tsai CY (2019) Semaphorin 3A in ankylosing spondylitis. J Microbiol Immunol Infect 52:151\u2013157. https:\/\/doi.org\/10.1016\/j.jmii.2017.07.001","journal-title":"J Microbiol Immunol Infect"},{"key":"5197_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/nature05652","volume":"446","author":"K Suzuki","year":"2007","unstructured":"Suzuki K, Okuno T, Yamamoto M et al (2007) Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature 446:680\u2013684. https:\/\/doi.org\/10.1038\/nature05652","journal-title":"Nature"},{"key":"5197_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/08820139.2019.1649280","volume":"49","author":"P Wang","year":"2020","unstructured":"Wang P, Mao YM, Liu LN et al (2020) Decreased expression of semaphorin 3A and semaphorin 7A levels and \u0131ts association with systemic lupus erythematosus. Immunol Invest 49:69\u201380. https:\/\/doi.org\/10.1080\/08820139.2019.1649280","journal-title":"Immunol Invest"},{"key":"5197_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American college of rheumatology\/European league against rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology \u0131nvolving three \u0131nternational patient cohorts. Arthritis Rheumatol 69:35\u201345. https:\/\/doi.org\/10.1002\/art.39859","journal-title":"Arthritis Rheumatol"},{"key":"5197_CR23","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/rheumatology\/keh714","volume":"44","author":"M Ramos-Casals","year":"2005","unstructured":"Ramos-Casals M, Font J (2005) Primary Sj\u00f6gren\u2019s syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 44:1354\u20131367. https:\/\/doi.org\/10.1093\/rheumatology\/keh714","journal-title":"Rheumatology (Oxford)"},{"key":"5197_CR24","doi-asserted-by":"publisher","first-page":"A820.2","DOI":"10.1136\/annrheumdis-2013-eular.2437","volume":"72","author":"Y Yoshida","year":"2013","unstructured":"Yoshida Y, Kang S, Morishima A et al (2013) AB0114 semaphorin3a and semaphorin4d in rheumatoid arthritis. Ann Rheum Dis 72:A820.2. https:\/\/doi.org\/10.1136\/annrheumdis-2013-eular.2437","journal-title":"Ann Rheum Dis"},{"key":"5197_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G et al (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46:625\u2013631. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.003","journal-title":"Semin Arthritis Rheum"},{"key":"5197_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1365-3083.2002.01129.x","volume":"56","author":"S Holmes","year":"2002","unstructured":"Holmes S, Downs AM, Fosberry A et al (2002) Sema7A is a potent monocyte stimulator. Scand J Immunol 56:270\u2013275. https:\/\/doi.org\/10.1046\/j.1365-3083.2002.01129.x","journal-title":"Scand J Immunol"},{"key":"5197_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13075-016-1217-5","volume":"19","author":"J Xie","year":"2017","unstructured":"Xie J, Wang H (2017) Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis. Arthritis Res Ther 19:10. https:\/\/doi.org\/10.1186\/s13075-016-1217-5","journal-title":"Arthritis Res Ther"},{"key":"5197_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40744-020-00264-x","volume":"8","author":"O Aiyegbusi","year":"2021","unstructured":"Aiyegbusi O, McGregor L, McGeoch L et al (2021) Renal disease in primary Sj\u00f6gren\u2019s syndrome. Rheumatol Ther 8:63\u201380. https:\/\/doi.org\/10.1007\/s40744-020-00264-x","journal-title":"Rheumatol Ther"},{"key":"5197_CR29","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/rheumatology\/kev223","volume":"54","author":"R Evans","year":"2015","unstructured":"Evans R, Zdebik A, Ciurtin C, Walsh SB (2015) Renal involvement in primary Sj\u00f6gren\u2019s syndrome. Rheumatol (United Kingdom) 54:1541\u20131548. https:\/\/doi.org\/10.1093\/rheumatology\/kev223","journal-title":"Rheumatol (United Kingdom)"},{"key":"5197_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","volume":"53","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zeron P, Solans R et al (2014) Systemic involvement in primary Sjogren\u2019s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 53:321\u2013331. https:\/\/doi.org\/10.1093\/rheumatology\/ket349","journal-title":"Rheumatology"},{"key":"5197_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.7861\/clinmedicine.14-2-157","volume":"14","author":"E Abrol","year":"2014","unstructured":"Abrol E, Gonzalez-Pulido C, Praena-Fernandez JM, Isenberg DA (2014) A retrospective study of long-term outcomes in 152 patients with primary Sjogren\u2019s syndrome: 25-year experience. Clin Med 14:157\u2013164. https:\/\/doi.org\/10.7861\/clinmedicine.14-2-157","journal-title":"Clin Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05197-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05197-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05197-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T16:02:54Z","timestamp":1682352174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05197-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["5197"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05197-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study approval was obtained from the ethics committee of Cumhuriyet University Medical Faculty (date: 11th July 2017, approval number: 2017-07\/08).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}